Kristensen KB, Hicks B, Azoulay L, et al. - A Danish population was used to confirm if angiotensin-converting enzyme inhibitor (ACEI) use is related to an greater risk of lung cancer. Data from four Danish national health and administrative registries were obtained to conduct a nested case-control study. In Denmark, Patients newly prescribed ACEIs or angiotensin II receptor blockers were observed from January 1, 2000 until December 31, 2015 for incident lung cancer, death, or emigration. For this study, they enrolled 9,652 lung cancer cases and matched them to 19,055 controls. Study results established an association between high use of ACEIs and lung cancer and revealed that modestly higher odds of lung cancer were reported in relation to use of high cumulative ACEI doses, while use of lower doses demonstrated neutral links. It is advised to consider the well-know advantages of ACEIs when interpreting these results.